For the “advantaged population” among patients with CHB or compensated cirrhosis, the clinical cure rate achieved with sequential or combined treatment with NAs and Peg-IFN-α-2b was greater than that of NA monotherapy (p < 0.001). The gene discussed is IFNA1; the disease is Cirrhosis.